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Background. We examined associations between suicidality and genotypes that predict plasma efavirenz exposure among AIDS 
Clinical Trials Group study participants in the United States.
Methods. Four clinical trials randomly assigned treatment-naive participants to efavirenz-containing regimens; suicidality was 
defined as reported suicidal ideation or attempted or completed suicide. Genotypes that predict plasma efavirenz exposure were 
defined by CYP2B6 and CYP2A6 polymorphisms. Associations were evaluated with weighted Cox proportional hazards models 
stratified by race/ethnicity. Additional analyses adjusted for genetic ancestry and selected covariates.
Results. Among 1833 participants, suicidality was documented in 41 in exposed analyses, and 34 in on-treatment analyses. In 
unadjusted analyses based on 12 genotype levels, suicidality increased per level in exposed (hazard ratio, 1.11; 95% confidence inter-
val, .96–1.27) and on-treatment 1.16; 1.01–1.34) analyses. In the on-treatment analysis, the association was strongest among white 
but nearly null among black participants. Considering 3 metabolizer levels (extensive, intermediate and slow), slow metabolizers 
were at increased risk. Results were similar after baseline covariate-adjustment for genetic ancestry, sex, age, weight, injection drug 
use history, and psychiatric history or recent psychoactive medication.
Conclusions. Genotypes that predict higher plasma efavirenz exposure were associated with increased risk of suicidality. 
Strength of association varied by race/ethnicity.
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Efavirenz is a frequently prescribed antiretroviral globally. 
Randomized clinical trials have demonstrated its efficacy [1–6]. 
However, some patients who start efavirenz experience central 
nervous system symptoms [7]. Among 5332 individuals who 
had been randomly assigned to start efavirenz-containing or efa-
virenz-free regimens in 4 AIDS Clinical Trials Group (ACTG) 
studies [8], efavirenz-containing regimens were associated with a 
2-fold increased hazard of suicidality. In the START trial, patients 
who started efavirenz-containing regimens had a higher incidence 
of suicidality than those who deferred therapy, a difference not 
seen in those starting nonefavirenz regimens [9]. In contrast, no 
association with suicidality was apparent in the Food and Drug 
Administration Adverse Event Reporting System [10], or in United 
States administrative claims data for commercially and Medicaid-
insured individuals [11]. In 2015, United States prescribing guide-
lines were updated to change efavirenz-containing regimens from 
recommended to alternative status as initial therapy for human 
immunodeficiency virus type 1 (HIV-1) infection [12].
Efavirenz is metabolized by cytochrome P450 (CYP) 2B6, 
with minor metabolism by CYP2A6 and CYP3A4/5 [13, 14], 
and direct N-glucuronidation by uridine diphosphate (UDP)-
glucuronosyltransferase (UGT) 2B7 [15]. Several CYP2B6 
polymorphisms, including 516G→T (rs3745274) [16–21], 
983T→C (rs28399499) [21–24], and 15582C→T (rs4803419), 
predict increased plasma efavirenz exposure [21]. The per 
allele effect is greatest with 983T→C and least with 15582C→T 
[21], such that combinations of the 3 polymorphisms predict 
10 plasma concentration strata that span an approximately 
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10-fold range [21]. Slow metabolizer CYP2B6 genotypes com-
prise the 3 highest strata, which are defined by either 516 T/T 
homozygosity, dual 516 G/T + 983 C/T heterozygosity, or 983 
C/C homozygosity.
Polymorphisms beyond CYP2B6, particularly CYP2A6, 
also affect efavirenz pharmacokinetics [25, 26]. Plasma efa-
virenz concentrations are increased with CYP2A6 -48T→G 
(rs28399433) [25–28], but only with concomitant CYP2B6 
slow metabolizer genotypes [25, 28]. A  possible association 
has also been reported with UGT2B7 genotype [27] although 
the effect size was small [28]. We examined whether genotypes 
known to predict increased plasma efavirenz exposure are 
associated with increased suicidality among individuals who 
were randomized to receive efavirenz-containing regimens in 
4 ACTG studies.
METHODS
Study Design and Participants
The study design was similar to that of previous nongenetic 
analyses characterizing relationships between efavirenz and 
suicidality in these ACTG studies [8]. Data were pooled from 
antiretroviral-naive individuals who started therapy in 4 stud-
ies that had randomly assigned participants to efavirenz-con-
taining versus efavirenz-free regimens: A5095 (ClinicalTrials.
gov: NCT00013520) [2, 29], A5142 (NCT00050895) [3], A5175 
(NCT00084136) [30], and A5202 (NCT00118898) [6]. Other 
than nucleoside analogue choice in A5142, drug class compo-
nents of the regimens were randomly assigned. The present 
analyses were also restricted to self-reported white, black, and 
Hispanic participants (classified according to National Institutes 
of Health categories) at ACTG sites in the United States (includ-
ing Puerto Rico). Genetic testing was restricted to participants 
who consented under ACTG protocol A5128 [31]. Other race/
ethnicity groups (eg, Asian) included too few individuals for 
analysis. Primary analyses were conducted among individuals 
assigned to efavirenz-containing regimens (hereafter called the 
efavirenz group), and a supplemental analysis included those 
assigned to efavirenz-free regimens for comparison (hereafter 
called the nonefavirenz group).
History of suicidal ideation or attempt was not exclusion-
ary. Protocols required reporting of signs, symptoms, or diag-
noses at each visit, which were recorded with open-text and 
data-entry codes. Each study required reporting of severe and 
life-threatening graded signs or symptoms per the Division 
of AIDS grading table [32], as well as signs or symptoms that 
led to change in study treatment. Diagnoses were not graded. 
Further, study A5142 required report of all moderate signs or 
symptoms, and A5095 and A5202 required report of moder-
ate central nervous system symptoms. Site institutional review 
boards approved each study, and participants provided written 
informed consent.
Outcomes
The primary outcome was suicidality, defined as suicidal ide-
ation or attempted or completed suicide and identified from 
signs, symptoms, diagnoses, adverse events, and death data as 
described in detail elsewhere [8]. Attempted or completed sui-
cide was a secondary outcome, as was suicidality or fatal injury 
attributed to substance abuse, homicide, accident, or unknown 
cause. The at-risk period started when antiretroviral treatment 
was initiated. For efavirenz-exposed analyses, subsequent fol-
low-up was included regardless of treatment status. For on-treat-
ment analyses, follow-up was censored at discontinuation of the 
randomly assigned efavirenz strategy, plus 28 days for washout.
Covariates
Baseline covariates included for adjustment were self-reported 
race/ethnicity (or, alternatively, genetic ancestry), sex, age cat-
egory, history of injection drug use, documented psychiatric 
history or use of psychoactive medication within 30 days before 
study entry, and body weight category. CD4 T-cell count, HIV-1 
RNA, and history of AIDS-defining event were also measured 
at baseline. Genome-wide genotype data were used to generate 
principal components that were also used as covariates to adjust 
for genetic ancestry, to minimize confounding by unrecognized 
population stratification (see Statistical Analysis section for 
details).
Genetic Assays and Data
Genotypes for CYP2B6 516G→T, 983T→C, 15582C→T and 
CYP2A6 -48T→G were largely available from a MassARRAY 
iPLEX Gold (Sequenom) assay, generated by Vanderbilt 
Technologies for Advanced Genomics (VANTAGE) as described 
elsewhere [21]. For additional participants who consented to 
genetic testing but lacked such data, CYP2B6/CYP2A6 geno-
typing was attempted with the same assay. Genome-wide gen-
otype data largely available from a previous immunogenomics 
project [33] were generated by Illumina HumanHap 650Y array 
for A5095 and by Illumina 1M duo array for A5142 and A5202. 
Quality control and imputation of genome-wide data were per-
formed essentially as described elsewhere [34]. To assure that 
genotypes could be combined across assays, 65 samples previ-
ously genotyped with HumanHap 650Y array or Illumina 1M 
duo array were regenotyped with Illumina Expanded Multi-
Ethnic Genotyping array (MEGAEX, with >2 million markers). 
There was high concordance across genotypes (r2 > 0.998) and 
the first 10 principal components (all r2 > 0.998), thus providing 
assurance. In addition, MEGAEX genotyping was attempted in 
participants with suicidality in whom genome-wide genotype 
data were not already available.
Efavirenz metabolizer categories were prespecified, and were 
defined by combinations of CYP2B6 and CYP2A6 polymor-
phisms [21, 28]. Two categorization approaches considered 
the full range metabolizer strata based on either CYP2B6 alone 
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(10 strata) or both CYP2B6 and CYP2A6 (12 strata). A  third 
approach collapsed the 12 strata into 3 groups, defined as 
extensive metabolizers (strata 1–2), intermediate metabolizers 
(strata 3–7), and slow metabolizers (strata 8 and higher). See 
Supplemental Material for details. Consent for genetic analysis 
was obtained under ACTG protocol A5128 [31], and the ACTG 
approved this use of DNA.
Statistical Analysis
Our aim was to estimate the association between efavirenz 
metabolizer genotype and suicidality among participants who 
started randomly assigned efavirenz-containing regimens for 
initial treatment of HIV-1 infection. The association between 
genotype level and time to suicidality outcomes was evaluated 
with a hazard ratio (HR) from a weighted Cox proportional 
hazards model, stratified by race/ethnicity group, with geno-
type level included as a linear covariate. To assess the linearity 
assumption, genotype level was also fit using a restricted qua-
dratic spline with 4 equally spaced knots at the 20th, 40th, 60th 
and 80th percentiles [35]. Furthermore, metabolizer genotype 
was fit as 3 unordered groups versus linear with 3 levels (exten-
sive, intermediate, slow); a likelihood ratio test did not provide 
evidence against the linear fit (P  =  .49 for efavirenz-exposed 
and P  =  .93 for efavirenz on-treatment analysis). Subsequent 
analyses include genotype as a linear covariate unless indicated 
otherwise.
Further analyses were conducted to adjust for genetic ances-
try among the subset of participants with genome-wide geno-
type data. To quantify ancestry among samples, we estimated 
continuous axes of ancestry incorporating the intersection of 
common autosomal genotypes across all genotyped sets used 
(n = 74 308 single-nucleotide polymorphisms) using the pro-
gram EIGENSTRAT version 6.1.4 [36]. Samples from the 
International HapMap Project [37] phase 3 were also included 
to provide global reference populations. The principal compo-
nents scree plots were visually examined to ensure that the com-
ponents selected for analyses represented ancestral information. 
The first 4 genetic ancestry principal components were included 
as covariates in a weighted Cox model that was not stratified 
by self-reported race/ethnicity; additional principal compo-
nents were not included to avoid model overfitting. Adjusted 
analyses included additional baseline covariates as described 
above. Race/ethnicity (and genetic ancestry) was the primary 
confounding factor and potential modifier of interest, and small 
event numbers limited the number of additional covariates in 
the adjustment set for multivariable analyses.
A supplemental analysis evaluated whether participants clas-
sified as efavirenz extensive metabolizers in the efavirenz group 
were at greater risk of suicidality than those who were randomly 
assigned to the nonefavirenz group. As with the efavirenz 
group, the nonefavirenz group was restricted to white, black, 
and Hispanic participants who enrolled in the United States or 
Puerto Rico and who consented to genetic testing. CYP2B6/
CYP2A6 testing was not conducted in the nonefavirenz group. 
A  2-sided 0.05 statistical significance level was used, with no 
adjustment for multiple testing. Statistical analyses were con-
ducted using Windows SAS (version 9.4) and R (version 3.3.1) 
software.
Weighting for Missing Data and Dropout
The 2239 participants who started randomly assigned efavirenz 
therapy were considered the full sample. Inverse probability 
missingness weights were used to adjust for 18% missing metab-
olizer genotype data and 38% missing genetic ancestry data 
[38]. Inverse probability censoring weights were used in Cox 
models to adjust for event-free dropout due to (1) premature 
study discontinuation for the exposed follow-up analyses and 
(2) premature discontinuation of the assigned efavirenz strat-
egy or study follow-up for on-treatment analyses [39]. For the 
exposed follow-up analyses, using inverse probability weights, 
we aimed to estimate the association between genotype level 
and suicidality in a setting where all participants who started 
efavirenz therapy had genetic data available and also completed 
study follow-up. For the on-treatment analyses, we aimed to 
estimate this same association in a setting where participants 
who started efavirenz therapy had genetic data available and 
remained on the efavirenz regimen and in follow-up for their 
full possible duration of study. Participants who could not con-
tinue owing to death or research site defunding were considered 
study completers.
Logistic regression was used to estimate missingness weights, 
and pooled logistic regression to estimate censoring weights. 
The product of these 2 weights was applied in a weighted Cox 
model using the robust variance estimator [40]. Five fully 
observed baseline covariates were included to estimate weights: 
sex, self-reported race/ethnicity, age (restricted quadratic 
spline), history of injection drug use, and psychiatric history 
or psychoactive medication. The missingness weights model 
included these 5 covariates plus an indicator of suicidality out-
come to account for differential data availability; the censoring 
weights model included these 5 covariates as well as CYP2B6/
CYP2A6 metabolizer level. Main effects and 2-way interactions 
(linear interactions for age) were included in the models to esti-
mate inverse probability of missingness and censoring weights.
RESULTS
Study Participants
A total of 2257 white, black, or Hispanic participants from 
ACTG studies A5095, A5142, A5175, and A5202 were randomly 
assigned to receive efavirenz-containing regimens at research 
sites in the United States and Puerto Rico, of whom 2239 started 
efavirenz therapy. After exclusion of those who did not provide 
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consent for genetic testing or were not successfully genotyped 
for CYP2B6 and CYP2A6, 1833 (82% of 2239) participants were 
evaluable for associations between CYP2B6/CYP2A6 genotype 
and suicidality. These included 41 (87% of 47) with suicidality 
and 1792 (82% of 2192) without suicidality. Of these 1833 par-
ticipants, 1386 also had ancestry principal components data, 
including 40 (85% of 47)  with suicidality and 1346 (61% of 
2192) without suicidality, the latter lower percentage reflecting 
our decision to generate ancestry principal components in as 
many participants with suicidality as possible, while relying on 
previously available genotype data to generate principal com-
ponents on those without suicidality. Participant disposition is 
presented in Figure 1.
Baseline characteristics and genotype frequencies are shown 
in Table 1. Among the 1833 participants with CYP2B6/CYP2A6 
genotype data, the median age was 38  years, and 18% were 
female, generally consistent with the remaining 406 individuals 
who did not have CYP2B6/CYP2A6 genotype data, except that 
those with CYP2B6/CYP2A6 genotype data were more likely to 
be white. Genotype frequencies in each race/ethnicity group are 
presented in Table 2. Slow metabolizer genotypes were present 
in 50 (6%) of 781 white, 120 (18%) of 660 black, and 45 (11%) of 
392 Hispanic participants.
Associations With Suicidality
Among the 1833 participants with CYP2B6/CYP2A6 genotype 
data, suicidality was documented in 41 (2.2%) over 4743 per-
son-years at risk in the efavirenz-exposed analysis (estimated 
incidence, 8.64/1000 person-years), and 34 (1.9%) over 3954 
person-years at risk in the on-treatment analysis (8.60/1000 
person-years). In unadjusted weighted analyses based on 12 
genotype levels defined by CYP2B6/CYP2A6 genotypes (our 
3834 white, black, or
Hispanic participants
enrolled in the US to
A5095, A5142, A5175,
or A5202
2257 white, black, or
Hispanic participants
enrolled in the US to
A5095, A5142, A5175,
or A5202, and
randomly assigned to
efavirenz-containing
regimens
2239 initiated efavirenz
1913 consented for
genetic testing
1833 with
CYP2B6/CYP2A6 genotype
data included in analyses
stratified by self-
identified race/ethnicity
1296 included in
analyses vs efavirenz
group extensive
metabolizers, stratified
by self-identified
race/ethnicity
1386 with principal
component data
included in analyses
adjusted for genetic
ancestry
Efavirenz group
1577 white, black, or
Hispanic participants
enrolled in the US to
A5095, A5142, A5175,
or A5202, and
randomly assigned to
nonefavirenz regimens
1565 initiated non
efavirenz regimen
1296 consented for
genetic testing
12 did not inititate a
nonefavirenz
regimen
269 did not consent
for genetic testing
Non-efavirenz group
18 did not initiate
efavirenz
326 did not consent for
genetic testing
80 without CYP2B6/
CYP2A6 genotype data
447 without PC data
Figure 1. Derivation of the study sample. Selection of the study population is shown among white, black, and Hispanic participants who were randomly assigned to an 
efavirenz-containing or nonefavirenz regimen in A5095, A5142, A5175, or A5202 and enrolled in the United States (US) or Puerto Rico. PC, principal component.
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most precise genetic estimate of plasma efavirenz exposure), 
the estimated hazard of suicidality was increased per level in 
both exposed (HR, 1.11; 95% confidence interval [CI], .96–1.27; 
P = .16) and on-treatment (1.16; 1.01–1.34; P = .04) analyses, 
although only the latter was statistically significant. 
There was significant effect measure modification by race/eth-
nicity in the on-treatment analysis, with the positive association 
between genotype level and suicidality being strongest among 
white, intermediate among Hispanic, and not present among 
black participants (P = .04). In the exposed analysis the pattern 
was similar, although the association was partially attenuated 
among white participants, and significant effect measure mod-
ification was not detected (P  =  .20) (Figure  2). To assess the 
assumption of linearity of the 12 genotype levels (which predict 
progressively higher plasma efavirenz exposure) and suicidality, 
genotype level was also fit using a restricted quadratic spline. 
Visual inspection of the spline fit provided support for the 
assumption of a linear association with no apparent threshold 
effect (Figure 3).
The estimated cumulative probability of suicidality based 
on 3 genotype levels is presented in Figure 4. Among all study 
participants, slow metabolizers were at numerically increased 
risk at each time point, with no apparent difference between 
intermediate and slow metabolizers during most of the study 
follow-up period (Figure  4A). This differed by race/ethnic-
ity. Among black participants, neither slow nor intermediate 
metabolizers seemed to be at greater risk than extensive metab-
olizers, whereas among white and Hispanic participants, there 
seemed to be an association between metabolizer level and 
suicidality, although there were relatively few Hispanic partic-
ipants (Figure 4B–4D). Table 3 presents results from weighted 
Cox models to estimate the association between genotype level 
and a suicidality outcome adjusted for self-identified race/
ancestry, as well as for psychiatric history or psychoactive med-
ication, injection drug use history, sex, age category, and body 
weight category.
The above analyses were stratified by self-identified race/eth-
nicity, which can introduce unrecognized population stratifica-
tion. Additional adjusted analyses controlled for genetic ancestry 
based on the first 4 principal components, as well as psychiat-
ric history/psychoactive medication, history of injection drug 
use, sex, age category, and body weight category. Among 1384 
participants (including white, black, and Hispanic participants) 
with both principal component and other covariate data, the 
HR estimate by genotype level for suicidality exceeded 1.0 in 
all analyses but was statistically significant only in on-treat-
ment analysis based on 3 metabolizer levels (HR, 1.74; 95% CI, 
1.02–2.97; P = .04). Results from weighted Cox models to esti-
mate the association between genotype level and a suicidality 
outcome adjusted for the first 4 principal components, as well 
as for psychiatric history or psychoactive medication, injection 
drug use history, sex, age category, and body weight category, 
are presented in Table 3. Results of weighted Cox models were 
similar in analyses that considered not only suicidality but also 
death from substance abuse, accident, or unknown cause (data 
not shown).
Comparison to Efavirenz-Free Regimens
We explored risk of suicidality among CYP2B6/CYP2A6 exten-
sive metabolizers versus individuals randomized to nonefa-
virenz regimens in these clinical trials, and who also consented 
to genetic testing. There were 12 (0.9%) suicidality events 
reported among 1296 individuals in the nonefavirenz group. 
Table 1. Baseline Characteristics of Study Participants Assigned to an 
Efavirenz-Containing Regimen
Characteristic
CYP2B6/CYP2A6 Genotype Data 
Available, No. (%)a
Overall, No. (%)a 
(n = 2239)Yes (n = 1833) No (n = 406)
Parent study
 A5095 635 (35) 105 (26) 740 (33)
 A5142 403 (22) 70 (17) 473 (21)
 A5175 104 (6) 32 (8) 136 (6)
 A5202 691 (38) 199 (49) 890 (40)
Sex
 Male 1510 (82) 316 (78) 1826 (82)
 Female 323 (18) 90 (22) 413 (18)
Race/ethnicity 
 White non-Hispanic 781 (43) 121 (30) 902 (40)
 Black non-Hispanic 660 (36) 166 (41) 826 (37)
 Hispanic 392 (21) 119 (29) 511 (23)
Age, y
 Median (IQR) 38 (31–44) 38 (30–44) 38 (31–44)
 Range 17–77 19–71 17–77
CD4 T-cell count, cells/μLb
 Median (IQR) 218 (75–330) 188 (64–295) 212 (73–322)
 Range 0–1336 1–849 0–1336
HIV-1 RNA, log10 copies/
mL
 Median (IQR) 4.74 (4.39–5.24) 4.74 (4.40–5.22) 4.74 (4.39–5.24)
 Range 2.34–7.04 2.76–6.71 2.34–7.04
History of AIDS   326 (18) 63 (16) 389 (17)
History of injection drug 
use   
174 (9) 49 (12) 223 (10)
Psychiatric history or psy-
choactive medication   
711 (39) 148 (36) 859 (38)
Psychoactive medication 310 (17) 69 (17) 379 (17)
Depression-related his-
tory or antidepressant 
medication 
459 (25) 94 (23) 553 (25)
Antidepressant 
medication 
239 (13) 53 (13) 292 (13)
Body mass index (kg/m2)c
 Median (IQR) 24.6 (22.0–27.8) 24.9 (22.2–27.9) 24.7 (22.1–27.8)
 Range 13.9–60.6 17.1–53.8 13.9–60.6
Abbreviations: HIV-1, human immunodeficiency virus type 1; IQR, interquartile range. 
aData represent No. (%) of participants unless otherwise specified.
bThis analysis included 2237 participants (1831 with and 406 without CYP2B6/CYP2A6 
genotype data available).
cThis analysis included 2205 participants (1810 with and 395 without CYP2B6/CYP2A6 gen-
otype data available).
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In on-treatment analyses, the hazard of suicidality was numer-
ically lower in the nonefavirenz group than in the extensive 
metabolizer group, although this difference was not statisti-
cally significant (HR, 0.70; 95% CI, .29–1.67; P = .42). The esti-
mated probability of suicidality in the nonefavirenz group was 
numerically lower than in the extensive metabolizer group at 
every time point. Among white participants, the likelihood of 
suicidality was similar in the extensive metabolizer and none-
favirenz groups. Among black participants, the number with 
suicidality was small in both the extensive metabolizer and 
nonefavirenz groups. Cumulative probabilities of suicidality 
in relation to the nonefavirenz group are in the Supplemental 
Material.
DISCUSSION
In ACTG studies, randomization to initial treatment with 
efavirenz-containing regimens was previously reported to be 
associated with a 2-fold increased hazard of suicidality [8]. The 
present study showed that, in analyses limited to white, black, 
and Hispanic participants randomly assigned to receive an efa-
virenz-containing regimen in those same studies, genotypes 
that predict increased plasma efavirenz exposure were also 
White
Events/Total Hazard Ratio (95% CI)
Per 1-Level Increase in CYP2B6/CYP2A6 (Levels 1–12)
Overall, exposed
Race/ethnicity
Overall, on-treatment
Race/ethnicity
Black
Hispanic
White
Black
Hispanic
23/781
41/1833
0.0 0.5 1.0 1.5 2.0
34/1833
12/660
6/392
17/781
11/660
6/392
1.21 (1.00–1.47)
1.11 (.96–1.27) .16
Results P Value
.20
.04
.04
1.16 (1.01–1.34)
0.94 (.76–1.16)
1.19 (.81–1.73)
1.37 (1.13–1.67)
0.93 (.75–1.16)
1.20 (.83–1.73)
Figure 2. Relative hazard of suicidality by genotype level among participants randomly assigned to efavirenz-containing regimens. Each incremental CYP2B6/CYP2A6 
genotype level (levels 1–12) is known to be associated with progressively greater plasma efavirenz exposure. The estimated relative hazard of suicidality is shown overall 
and within each race/ethnicity group, for both exposed and on-treatment risk periods. Overall P values test reflect the main effect of genotype level; race/ethnicity P values, 
a statistical interaction between genotype level and race/ethnicity group. Hazard ratios were estimated from a weighted Cox model stratified by race/ethnicity; robust Wald 
confidence intervals (CIs) and P values are shown.
Table 2. Genotype Frequencies According to Self-Identified Race/Ethnicity
Metabolizer
Level
CYP2B6
CYP2A6: 
-48T→G
White  
(n = 781)
Black  
(n = 660)
Hispanic  
(n = 392)
Overall  
(n = 1833)15582C→T 516G→T 983T→C
Extensive 355 (45) 218 (33) 115 (29) 688 (38)
 1 CC GG TT - 166 (21) 137 (21) 41 (10) 344 (19)
 2 CT GG TT - 189 (24) 81 (12) 74 (19) 344 (19)
Intermediate 376 (48) 322 (49) 232 (59) 930 (51)
 3 TT GG TT - 94 (12) 12 (2) 68 (17) 174 (9)
 4 CC GT TT - 176 (23) 198 (30) 69 (18) 443 (24)
 5 CC GG CT - 0 (0) 45 (7) 1 (0) 46 (3)
 6 CT GT TT - 106 (14) 57 (9) 93 (24) 256 (14)
 7 CT GG CT - 0 (0) 10 (2) 1 (0) 11 (1)
Slow 50 (6) 120 (18) 45 (11) 215 (12)
 8 CC TT TT - 47 (6) 81 (12) 40 (10) 168 (9)
 9 CC GT CT - 0 (0) 15 (2) 2 (1) 17 (1)
 10 CC GG CC - 0 (0) 2 (0) 0 (0) 2 (0)
 11 Level 8, 9, or 10 GT 2 (0) 22 (3) 3 (1) 27 (1)
 12 Level 8, 9, or 10 GG 1 (0) 0 (0) 0 (0) 1 (0)
Total
Data are no. (%).
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associated with increased suicidality. This finding further sup-
ports the validity of the reported association between efavirenz 
and suicidality [8]. In addition, the genetic association with sui-
cidality progressively increased by CYP2B6/CYP2A6 genotypes 
that predict progressively higher plasma efavirenz concentra-
tions with no apparent threshold, suggesting that increased sui-
cidality is not limited to CYP2B6 slow metabolizers. Our study 
also showed an apparent difference in the on-efavirenz treat-
ment association between genetics and suicidality depending 
on race/ethnicity, with an association among white participants 
(HR. 1.37; 95% CI, 1.13–1.67) but not black participants (0.93; 
.75–1.16). This analysis included fewer Hispanic participants, 
but their risk seemed to be intermediate (HR, 1.20; 95% CI, 
.83–1.73).
This study replicates a difference by race first noted in a much 
smaller ACTG data set [24] in which there was an association 
between CYP2B6 slow metabolizer genotypes and increased 
central nervous system adverse events in 276 white participants 
(P = .04) but not in 217 black participants (P = .58). A subse-
quent observational study involving 563 patients who started 
efavirenz-containing regimens at a clinic in the southeastern 
United States found that slow metabolizer CYP2B6 genotypes 
were associated with efavirenz discontinuation for reported 
central nervous system symptoms in 335 white participants 
(P = .001) but not in 198 black participants (P = .27) [41]. These 
previous studies, together with the present study, suggest that 
among patients with intermediate or slow metabolizer geno-
types who are prescribed efavirenz in the United States, central 
nervous system side effects, including suicidality, are more likely 
to be reported among white than among black participants. 
Among Hispanic participants, CYP2B6/CYP2A6 genotype 
level also seemed to be associated with increased suicidality, 
although this association was not statistically significant and 
the confidence interval was wide, reflecting the small number 
of events in these analyses.
We cannot explain the stronger association of CYP2B6/CYP2A6 
slow metabolizer genotypes with suicidality among white com-
pared with black participants. Black participants with suicidality 
may have been less likely to report such symptoms than white 
participants with similar symptoms, resulting in misclassifi-
cation. Plasma efavirenz exposure is similar among black and 
white individuals with CYP2B6 slow metabolizer genotypes 
[21], so differences in such exposure are unlikely to explain the 
attenuated genetic association in blacks compared with whites. 
It is also possible that polymorphisms in genes beyond CYP2B6 
affect susceptibility to suicidality with efavirenz.
Genetic testing has the potential to identify patients in whom 
drugs with unfavorable adverse event profiles may be safely pre-
scribed. This was the rationale for exploring whether extensive 
metabolizers (ie, lower-risk subgroup) in the efavirenz group 
were still at greater risk of suicidality than participants in the 
nonefavirenz group. The numerically lower probability of sui-
cidality in the nonefavirenz group at each study time point 
overall supports the validity of the association between CYP2B6 
genotype level and suicidality in the efavirenz group. Although 
among white participants the likelihood of suicidality was sim-
ilar in the extensive metabolizer and nonefavirenz groups, the 
small number of participants with suicidality in both groups 
prevents us from concluding that CYP2B6 genotyping can iden-
tify patients at no increased risk of suicidality with efavirenz 
versus nonefavirenz regimens.
Unrecognized population stratification can cause spurious 
associations in genetic epidemiology studies. We addressed this 
by not only considering self-identified race/ethnicity but by also 
separately adjusting for principal components generated from 
genome-wide genotype data. Associations persisted in the latter 
analyses. In addition, the genetic association persisted in multi-
variable models that also included sex, age category, history of 
injection drug use, psychiatric history or psychoactive medica-
tion, and body weight category (all measured at baseline).
Our study had limitations. Because data were from clini-
cal trials that did not specifically focus on suicidality, we may 
have missed some suicidality cases. To help address the possi-
bility that suicidality was underreported, we included suicid-
ality plus death from substance abuse, accident, or unknown 
cause in sensitivity analyses. Because providers may not have 
referred participants considered to be at high risk for neu-
rologic intolerance to studies with efavirenz-containing reg-
imens, risk of suicidality may be underestimated. Analyses 
were limited to white, black, and Hispanic participants at sites 
in the United States, so findings may not translate to other 
countries or race/ethnicities, including Asians. The open-label 
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Figure 3. Genotype level fit with a quadratic spline. CYP2B6/CYP2A6 genotype 
level was fit with a quadratic spline with 4 equally spaced knots at levels 2, 3, 4, and 
6, as indicated by downward arrows. Each hash mark represents the participant’s 
observed genotype level (n = 1833); solid line, the estimated relative hazard; and 
dashed lines, pointwise 95% Wald-type confidence intervals from a weighted Cox 
model stratified by race/ethnicity group. This provides support for the assumption of 
a linear association with no apparent threshold effect. The unweighted result was 
similar and slightly closer to linear (data not shown).
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design of 3 of the 4 studies might have biased investigators 
into reporting neuropsychiatric effects in patients randomized 
to efavirenz.
In summary, CYP2B6/CYP2A6 genotypes were associated 
with increased reported suicidality among participants who 
had been randomly assigned to receive efavirenz-containing 
regimens in clinical trials. This association was most appar-
ent in white participants and attenuated in black participants.
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